NEKTAR THERAPEUTICSNKTR

時価総額
$3.3億
PER
2011年
12月31日
2012年
12月31日
2013年
12月31日
2014年
12月31日
2015年
12月31日
2016年
12月31日
2017年
12月31日
2018年
12月31日
2019年
12月31日
2020年
12月31日
2021年
12月31日
2022年
12月31日
Net loss-------681-441-444-524-368
Non-cash royalty revenue related to the sales of future royalties-11335577107138171207256333403
Non Cash Interest Expense Related To Sale Of Royalties---6182102120142167197244273
Loss on revaluation of liability related to the sale of future royalties-----------24-
Change in fair value of development derivative liability-----------833
Research and Development in Process----------175
Stock-based compensation---1720263788100949557
Depreciation and amortization151514131315151113141413
Deferred income tax expense---------0-0-03
Asset Impairment Charges-----------66
(Gain) loss on sale or disposal of property, plant and equipment, net-----------3
Impairment Of Equipment From Terminated Program------15--20--
Amortization of premiums (discounts), net and other non-cash transactions-----------72
Accounts receivable-201-4116-4-1126-6-2-12-17
Inventory56-5-0-2-0-011313
Operating leases, net---------13-3-23
Other assets12-6-6310532-1-43-7
Accounts payable-3-06-6-0121132-123
Accrued compensation4-45-9012-102251-6
Other accrued expenses-----2062849-24-13
Deferred revenue--------15-17-6-1-1
Net cash used in operating activities-114-130-39----718-329-313-413-304
Purchases of investments-------2,2711,381988961468
Maturities of investments3833083192482272543488911,6141,4491,167826
Sales of investments-------12-4212-
Purchases of property, plant and equipment10114101161014267156
Sales of property, plant and equipment-------3---13
Net cash provided by investing activities-11211350-----1,380207496203366
Proceeds From Sale of Future Royalties, Net---------146--
Repayment of senior notes----125----250--
Cash receipts from development derivative liability----------31
Proceeds from shares issued under equity compensation plans-4847322060622323331
Net cash provided by (used in) financing activities222272----85223-80362
Effect of foreign exchange rates on cash and cash equivalents---------00-0-0
Net increase (decrease) in cash and cash equivalents-------190-99103-17463
Cash paid for interest-------191910--
Income Taxes Paid, Net111111111100
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability--------5821-